Moteur de recherche d’entreprises européennes
Financement de l’UE (4 130 611 €) : Réseau de formation pour le suivi et le contrôle des cellules immunitaires thérapeutiques dans le cancer Hor02/08/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Réseau de formation pour le suivi et le contrôle des cellules immunitaires thérapeutiques dans le cancer
Cancer immunotherapies have been established in a growing number of clinical indications and the pace of development is massively accelerating. Currently over 6.000 clinical trials are investigating immune-related treatments in oncology especially in combinations. It includes both adoptive cellular therapies and immune modulating treatments like immune check point blockade. In contrast, the understanding of how such therapies mediate their mode of action is still mostly poorly understood. In particular, the role of distribution and relocation of immune cells after therapeutic interventions remains unknown. This is surprising, as immune cell interactions are a hallmark of therapeutic immune responses. T-RAFIC will enhance understanding of immune cell trafficking under therapeutic influence. It will open new paths and avenues to treatments, boost their efficacy and help prioritizing the plethora of immune therapeutic combinations. In the past, detailed analysis of cellular distributions was facing technical barriers. Advances in technologies, now permit tracking and visualization of cells in vitro and in vivo at an unprecedented resolution, allowing for the first time studies on immune cells under therapeutic influence. This emerging field of research has enormous potential and key importance for next generation of researchers in oncology and beyond. However, experts in this field are missing and this threats European research, development and medicine. Therefore, T-RAFIC joins forces of 19 academic and three industrial partners from nine European countries to conduct an innovative and interdisciplinary approach combining cell imaging with bioinformatics, cell engineering and clinician expertise. The network bundles recognised expertise in cancer immunotherapies, empowering European research and innovation and ensuring a sustainable cooperation in science and training.
| Anglia Ruskin University | ? |
| Danmarks Tekniske Universitet | 301 788 € |
| Institut Gustave Roussy | 282 694 € |
| Institut National de la Sante et de la Recherche Medicale | 565 387 € |
| Klinikum DER Technischen Universität München (TUM Klinikum) | 260 539 € |
| Ludwig-Maximilians-Universitaet Muenchen | 781 618 € |
| Medizinische Universitat Innsbruck | 270 331 € |
| Miltenyi Biotec B.V. & Co. KG | 260 539 € |
| Oslo Universitetssykehus HF | 297 749 € |
| Region Hovedstaden | 301 788 € |
| Stichting Amsterdam UMC | 548 741 € |
| Universita Humanitas | 259 438 € |
https://cordis.europa.eu/project/id/101168810
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Anglia Ruskin University, Chelmsford, Royaume Uni.